| Detected | Trial | Change |
|---|---|---|
| 2026-06-06 | NCT06901531 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… |
Trial sites expanded: 238 -> 246 locations |
| 2026-05-29 | NCT06901531 A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… |
Trial sites expanded: 224 -> 238 locations |
| 2026-05-28 | NCT07431281 Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in… |
Trial sites expanded: 258 -> 269 locations |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07431281 | Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in… | Gastric Cancer | Recruiting |
| NCT06901531 | A Study of Zolbetuximab Together With Pembrolizumab and Chemotherapy in Adults With… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Recruiting |
| NCT03653507 | A Study of Zolbetuximab (IMAB362) Plus CAPOX Compared With Placebo Plus CAPOX as… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Active, Not Recruiting |
| NCT03504397 | A Study to Compare Zolbetuximab (IMAB362) and Chemotherapy With Placebo and Chemotherapy… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Active, Not Recruiting |
| Phase 2 | |||
| NCT06468280 | Synergistic Effects of PD-1 Antibody and Chemotherapy/Targeted Therapy Followed by… | Gastric Cancer | Recruiting |
| NCT03505320 | A Study of Zolbetuximab (IMAB362) in Adults With Gastric Cancer | Pharmacokinetics of Zolbetuximab | Active, Not Recruiting |
| NCT03816163 | A Study of Zolbetuximab (IMAB362) in Adults With Pancreatic Cancer | Pancreatic Cancer | Active, Not Recruiting |
| Not specified | |||
| NCT06902545 | A Study to Observe the Safety of VYLOY (Zolbetuximab) in People in South Korea With… | Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Cancer | Recruiting |